AbbVie's Commitment to Oncology Demonstrated at the 57th American Society of Hematology Annual Meeting with 61 Abstracts Evaluating Medicines in Several Blood Cancers - New data evaluating investigational compound venetoclax as monotherapy and in combination for the treatment of several blood cancers to be presented; AbbVie recently completed submission of NDA for venetoclax to the FDA- Results from several clinical trials evaluating ibrutinib (IMBRUVICA®) in multiple hematological malignancies accepted for oral presentation

NORTH CHICAGO, Ill., Nov. 5, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a leading biopharmaceutical company, will present data from clinical trials evaluating the company's oncology portfolio during the 57th American Society of Hematology Annual Meeting (ASH), December 5-8, in Orlando, Fla. Notably, data scheduled for presentation include results from studies of venetoclax, an investigational oral B-cell lymphoma-2 (BCL-2) inhibitor, in chronic lymphocytic leukemia (CLL) and other hematological malignancies. Additionally, researchers will present data from studies of ibrutinib (IMBRUVICA®), an inhibitor of Bruton's tyrosine kinase (BTK), as a single-agent and in combination with other...